Massive Bio Unveils Patient Connect for Personalized Global Cancer Trial Access
Massive Bio, a global leader in AI-driven cancer clinical trial enrollment, has launched Patient Connect, a new free portal designed to streamline cancer patients’ access to clinical trials worldwide. Patient Connect allows patients to find suitable clinical trials in their…
Kopin Launches SXGA-R15 Microdisplay for 3D Automated Optical Inspection
Kopin Corporation (NASDAQ: KOPN), a leading provider of optical systems and high-performance microdisplays for various sectors, has unveiled its next-generation drive board, the “R15,” for the SXGA FLCoS microdisplay. The new SXGA-R15 is tailored for 3D Automated Optical Inspection (AOI)…
Novotech Appoints Dr. Yooni Kim as Managing Director for Asia Pacific
Novotech, an international contract research organization (CRO), has announced the appointment of Dr. Yooni Kim as Managing Director of the Asia Pacific (APAC) region, effective September 1, 2024. This strategic move underscores Novotech’s commitment to expanding its global presence and…
Oticon Medical Wins Hearing Technology Innovator Award for Sentio™ System
Oticon Medical is pleased to announce that its Sentio System has been honored with the Hearing Technology Innovator Award™ in the category of Auditory Implants: Bone Conduction at the fifth annual awards ceremony. The Hearing Technology Innovator Awards™, hosted annually…
Hackensack Meridian Health Partners with K Health to Redefine Primary Care
Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network, is set to launch HMH 24/7, an AI-driven solution designed to enhance primary care by seamlessly integrating virtual and in-person services. This initiative reflects Hackensack Meridian Health’s commitment to…
ImmunoPrecise Antibodies (IPA) Announces Q1 Fiscal 2025 Financial Results and Highlights
ImmunoPrecise Antibodies Ltd (IPA) (NASDAQ: IPA), a biotherapeutics research and technology company utilizing artificial intelligence, has reported its financial results for the first quarter of fiscal 2025, ending July 31, 2024. All figures are presented in Canadian dollars (CAD) unless…
Delcath Presents New Data on HEPZATO KIT™ Efficacy in Metastatic Uveal Melanoma at ESMO 2024
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company specializing in liver-targeted cancer therapies, announced new subgroup analysis data from the FOCUS Phase 3 trial of HEPZATO KIT™ (melphalan/Hepatic Delivery System) in patients with metastatic uveal melanoma (mUM). The data…
Cellworks Biosimulation Boosts IO Response Predictions in NSCLC Patients
Cellworks Group Inc., a leader in personalized therapy decision support and precision drug development, has announced promising results from a study using its computational biosimulation to predict immunotherapy (IO) responses in non-small cell lung cancer (NSCLC) patients. By combining biosimulation…
RevBio Secures $2.4M NIH Grant for Bone Adhesive Trial, Enrolls First 5 Patients
RevBio, Inc. has secured a $2.4 million Phase II SBIR grant from the National Institute of Neurological Disease and Stroke (NINDS), part of the NIH. The two-year grant will support a 20-patient pilot clinical trial to evaluate the safety and…
CVS Pharmacy® Introduces Birth Control Prescribing in Massachusetts
CVS Health® (NYSE: CVS) has announced that CVS Pharmacy® locations in Massachusetts are now offering hormonal contraceptive prescribing services. Patients seeking birth control can be evaluated by a CVS pharmacist and, if eligible, receive a prescription directly from the pharmacy.…
CareDx Announces Inducement Grants per Nasdaq Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine for transplant patients, announced today that it granted restricted stock units (RSUs) totaling 44,000 shares to 14 new employees on September 12, 2024, as an inducement for joining the company. These…
Tempus to Present Four Abstracts at ESMO 2024
Tempus AI, Inc. (NASDAQ: TEM), a leader in using AI for precision medicine, has announced that four of its abstracts have been accepted for the European Society for Medical Oncology (ESMO) Congress 2024. The event will take place in Barcelona,…